Lack of effect of coenzyme Q10 on doxorubicin cytotoxicity in breast cancer cell cultures

Integrative Cancer Therapies

Volumn 11, Issue 3, 2012, Pages 243-250

  Greenlee, Heather ^a   Shaw, Jacquelyn ^a   Lau, Ying Ka Ingar ^a   Naini, Ali ^a   Maurer, Matthew ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

adriamycin; breast cancer; coenzyme Q10; cytotoxicity; doxorubicin; in vitro

Indexed keywords

DOXORUBICIN; UBIDECARENONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INTRACELLULAR SPACE; MITOCHONDRION; PRIORITY JOURNAL; SUPPLEMENTATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HUMANS; MITOCHONDRIA; UBIQUINONE;

EID: 84870457971     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735412439749     Document Type: Article

References (20)

1. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005 ; 23: 7811-7819 (Pubitemid 46657378)
2. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011 ; (6). CD003917
3. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005 ; 4: 110-130 (Pubitemid 40731561)
4. Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta. 2000 ; 302 (1-2). 1-9
5. Karlsson J, Folkers K, Astrom H Biomedical and Clinical Aspects of Coenzyme Q. Folkers K Yamamura Y, ed. Amsterdam, Netherlands: Elsevier/North-Holland Biomedical Press ; 1986: 241-245.
6. Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (ubiquinone). Regul Toxicol Pharmacol. 2006 ; 45: 282-288 (Pubitemid 44066629)
7. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992 ; 1126: 247-254
8. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 ; 56: 185-229 (Pubitemid 38720829)
9. Heaney ML, Gardner JR, Karasavvas N, et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 2008 ; 68: 8031-8038
10. Brea-Calvo G, Rodriguez-Hernandez A, Fernandez-Ayala DJ, Navas P, Sanchez-Alcazar JA. Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines. Free Radic Biol Med. 2006 ; 40: 1293-1302
11. Naini A, Lewis VJ, Hirano M, DiMauro S. Primary coenzyme Q10 deficiency and the brain. Biofactors. 2003 ; 18: 145-152 (Pubitemid 38030709)
12. Quinzii C, Naini A, Salviati L, et al. A mutation in para- hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet. 2006 ; 78: 345-349 (Pubitemid 43157573)
13. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun. 1997 ; 234: 296-299 (Pubitemid 27243894)
14. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006 ; 1: 2315-2319
15. Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res Treat. 2009 ; 115: 437-452
16. Greenlee H, Gammon MD, Abrahamson PE, et al. Prevalence and predictors of antioxidant supplement use during breast cancer treatment: the Long Island Breast Cancer Study project. Cancer. 2009 ; 115: 3271-3282
17. GreenleeHKwanMLKushiLH. Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. Cancer. In press.
18. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol. 2008 ; 26: 665-673 (Pubitemid 351264364)
19. Mursu J, Robien K, Harnack LJ, Park K, Jacobs DR. Dietary supplements and mortality rate in older women: the Iowa Women's Health Study. Arch Intern Med. 2011 ; 171: 1625-1633
20. Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 ; 306: 1549-1556